Genesis Biopharma and Lonza Sign Agreement for Metastatic Melanoma Treatment

Lonza is in partnership with Genesis Biopharma to develop Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

Genesis Biopharma, a biotechnology company developing targeted cancer therapies, and Lonza, a major supplier to the pharmaceutical, healthcare and life science industries, have announced their signing of a process development and scale-up agreement for the manufacture of Contego, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

Contego is a ready-to-infuse cell therapy based on currently available therapies at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.  "We are pleased to have such an experienced bioprocess development and manufacturing partner as Lonza," said Anthony J. Cataldo, chairman and chief executive officer of Genesis Biopharma. 

&nb